Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    abeona | Mucopolysaccharidosis III
Previous Study | Return to List | Next Study

Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04088734
Recruitment Status : Recruiting
First Posted : September 13, 2019
Last Update Posted : February 11, 2020
Sponsor:
Information provided by (Responsible Party):
Abeona Therapeutics, Inc

Tracking Information
First Submitted Date  ICMJE September 11, 2019
First Posted Date  ICMJE September 13, 2019
Last Update Posted Date February 11, 2020
Actual Study Start Date  ICMJE October 29, 2019
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 11, 2019)
  • Adverse Events and Serious Adverse Events [ Time Frame: 24 months ]
    The incidence, type, and severity of treatment-related adverse events and serious adverse events
  • CSF Heparan Sulfate [ Time Frame: 1, 6, 12, 24 months ]
    Change from baseline in CSF heparan sulfate levels after treatment
  • Liver and/or Spleen Volumes [ Time Frame: 1, 6, 12, 24 months ]
    Change from baseline in liver and/or spleen volumes after treatment, as measured by MRI
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 11, 2019)
  • Glycosaminoglycans or Heparan Sulfate [ Time Frame: 1, 6, 12, 18, 24 months ]
    Change from baseline in plasma or urine glycosaminoglycans or heparan sulfate after treatment
  • SGSH Enzyme Activity [ Time Frame: 1, 6, 12, 24 Months ]
    Change from baseline in CSF or plasma or leukocyte SGSH enzyme activity levels after treatment
  • Brain Volume [ Time Frame: 1, 6, 12, 24 months ]
    Change from baseline in brain volume after treatment, as measured by MRI
  • Developmental Age [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in the Developmental Age after treatment compared to Natural History Study data calculated by the Mullen Scales of Early Learning or the Kaufman Assessment Battery for Children, 2nd edition, based on chronological and developmental age
  • Cognitive Developmental Age [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in the Cognitive Developmental Age after treatment compared to Natural History Study, calculated using the Bayley Scales of Infant and Toddler Development - Third edition or the Kaufman Assessment Battery for Children. Second Edition, based on developmental age
  • Adaptive Age Equivalent Score [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in the Adaptive Age Equivalent score after treatment compared to Natural History Study data, as assessed by parent report using the Vineland Adaptive Behavior Scale II Survey form
  • Sanfilippo Behavior Rating Scale [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in the Sanfilippo Behavior Rating Scale
  • Sleep Pattern [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in sleep pattern as measured by the modified Children's Sleep Habits Questionnaire (CSHQ)
  • Pediatric Quality of Life Inventory [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in Pediatric Quality of Life Inventory (PedsQL™) Core Generic Scales total score
  • Parent Quality of Life [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in parent quality of life, using the Parenting Stress Index, 4th Edition (PSI-4)
  • Gastrointestinal Symptoms [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in gastrointestinal symptoms using the PedsQL™ Gastrointestinal Symptoms Scales
  • Parent Global Impression Score [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in Parent Global Impression Score
  • Clinical Global Impression Improvement Scale [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in Clinical Global Impression Improvement Scale
  • Parent Symptoms Score Questionnaire [ Time Frame: 6, 12, 18, 24 months ]
    Change from baseline in Parent Symptoms Score Questionnaire
  • Body Mass Index [ Time Frame: 6, 12, 18, 24 months ]
    Change from Baseline in Body Mass Index after treatment
  • EEG Monitoring [ Time Frame: 6, 12, 18, 24 months ]
    Incidence and Change from baseline in abnormalities in standard awake 60-minutes- EEG monitoring
  • AAV9 Viral DNA Detection [ Time Frame: 24 months ]
    Detection of the AAV9 viral DNA in plasma, saliva, urine and feces will be performed until two consecutive samples are negative
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
Official Title  ICMJE A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients With Middle and Advanced Phases of MPS IIIA Disease
Brief Summary Open-label, clinical trial of scAAV9.U1a.hSGSH injected intravenously through a peripheral limb vein
Detailed Description This is an open-label, single dose clinical trial. All participants will receive 3 X 10^13 vg/kg of ABO-102 delivered one time through a venous catheter inserted into a peripheral limb vein. The target population includes MPS IIIA participants with a DQ lower than 60 in middle and advanced phases of the disease. Similar numbers of MPS IIIA participants with age equivalent above and below 18 months of age will be enrolled to ensure a representation of middle and advanced phases of the disease.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • MPS IIIA
  • Sanfilippo Syndrome
  • Sanfilippo A
  • Mucopolysaccharidosis III
Intervention  ICMJE Drug: ABO-102
Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10^13 vg/kg
Other Name: scAAV9.U1a.hSGSH
Study Arms  ICMJE Experimental: ABO-102
Intervention: Drug: ABO-102
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 11, 2019)
12
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2022
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of MPS IIIA confirmed by the following methods:

    1. No detectable or significantly reduced SGSH enzyme activity by leukocyte assay and
    2. Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the SGSH gene
  • Cognitive Development Quotient (DQ) lower than 60 (calculated by Bayley Scales of Infant and Toddler Development - Third Edition)
  • Must be ambulatory, though may receive assistance with ambulation

Exclusion Criteria:

  • Inability to participate in the clinical evaluation as determined by Principal Investigator
  • Identification of two nonsense or null variants on genetic testing of the SGSH gene
  • At least one S298P mutation in the SGSH gene
  • Has evidence of an attenuated phenotype of MPS IIIA
  • Presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics
  • Active viral infection based on clinical observations
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer, or precludes the child from participating in the protocol assessments and follow up
  • Participants with total anti-AAV9 antibody titers greater than or equal to 1:100 as determined by ELISA binding immunoassay
  • Participants with a positive response for the ELISPOT for T-cell responses to AAV9
  • Serology consistent with exposure to HIV, or serology consistent with active hepatitis B or C infection
  • Bleeding disorder or any other medical condition or circumstance in which a lumbar puncture (for collection of CSF) is contraindicated according to local institutional policy
  • Visual or hearing impairment sufficient to preclude cooperation with neurodevelopmental testing
  • Any item (braces, etc.) which would exclude the participant from being able to undergo MRI according to local institutional policy
  • Any other situation that precludes the participant from undergoing procedures required in this study
  • Participants with cardiomyopathy or significant congenital heart abnormalities
  • The presence of significant non-MPS IlIA related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study
  • Abnormal laboratory values Grade 2 or higher as defined in CTCAE v4.0 for GGT, total bilirubin (except in subjects diagnosed with Gilbert's syndrome), creatinine, hemoglobin, WBC count, platelet count, PT and aPTT
  • Female participant who is pregnant or demonstrates a positive urine or beta-hCG result at screening assessment (if applicable)
  • Any vaccination with viral attenuated vaccines less than 30 days prior to the scheduled date of treatment (and use of prednisolone)
  • Previous treatment by Haematopoietic Stem Cell transplantation
  • Previous participation in a gene/cell therapy or ERT clinical trial
  • Participants who are anticipated to undergo a procedure involving anesthesia within 6 months post- drug administration
  • Dysphagia present at Grade 3 or higher, as defined in CTCAE v4.0
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Medical Affairs +1 646-813-4701 sanfilippo@abeonatherapeutics.com
Listed Location Countries  ICMJE Australia,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04088734
Other Study ID Numbers  ICMJE ABT-003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Abeona Therapeutics, Inc
Study Sponsor  ICMJE Abeona Therapeutics, Inc
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Abeona Therapeutics, Inc
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP